IsisCB Explore

Article ID: CBB938616624

Special Treatment? Flexibilities in the Politics of Regenerative Medicine’s Gatekeeping Regimes in the UK (2019)

Faulkner, Alex (Author)

Science as Culture
Volume: 28
Issue: 2
Pages: 149-173

URI: https://doi.org/10.1080/09505431.2017.1300641

DOI: 10.1080/09505431.2017.1300641

Outside Links

PubMed

WorldCat

Google Scholar

JSTOR

Academia.edu

Emerging flexibilities are apparent in gatekeeping regimes applicable to regenerative medicine products, raising issues about the extent to which and forms in which such flexibilities might promote emerging products as a sector warranting special treatment, in the context of recent policy developments in the UK and wider European Union. Concepts of ‘gatekeeping’, ‘gatekeeping regimes’ and ‘gateways’ can point to the ways in which regulatory institutions, health technology assessment organisations, and national planners and purchasers of health services together define and control entry to the medical product marketplace and the adoption of products into the public health-care system. Flexibilities in existing regimes and new gateways are a way of maintaining ‘connection’ between gatekeeping regimes and technoscientific innovation in order to steer innovation pathways. The gateways concept has affinity with that of Callon’s ‘obligatory passage points’. A wide set of recent policy documents show that the measures promoted exhibit a range of alternative gateways that are being constructed around central, legal, restrictive gatekeeping regimes. However, it would be easy to overestimate the significance of these developments as relaxations that would favour innovative producers and their products on a large scale with wide public health impacts. The concepts of gatekeeping regimes and gateways enable understanding of hybrid developments of exceptions and exemptions to dominant regimes which bridge across the arenas of market regulation, health technology assessment and health-care system planning. These arenas are being drawn closer together as a means of politically managing stakeholders’ aims in the UK, EU and other innovating biomedical health systems globally.

...More

Included in

Article Achim Rosemann (2019) Alter-Standardizing Clinical Trials: The Gold Standard in the Crossfire. Science as Culture (pp. 125-148). unapi

Citation URI

https://data.isiscb.org/isis/citation/CBB938616624/

Citations Indexes

Similar Citations

Article Sonja Erikainen; Anna Couturier; Sarah Chan; (2020)
Marketing Experimental Stem Cell Therapies in the UK: Biomedical Lifestyle Products and the Promise of Regenerative Medicine in the Digital Era (/isis/citation/CBB771315477/)

Article Margaret Sleeboom-Faulkner; (June 2019)
Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine (/isis/citation/CBB470996355/)

Article John Gardner; (September 2017)
Accelerating Innovation in the Creation of Biovalue: The Cell and Gene Therapy Catapult (/isis/citation/CBB000462445/)

Article Virginia Berridge; (2022)
The Many Endings of Recent Epidemics: HIV/AIDS, Swine Flu 2009, and Policy (/isis/citation/CBB473200788/)

Article Koichi Mikami; (2015)
State-Supported Science and Imaginary Lock-in: The Case of Regenerative Medicine in Japan (/isis/citation/CBB782339019/)

Article Bronwyn Parry; (January 2018)
The Social Life of “Scaffolds” Examining Human Rights in Regenerative Medicine (/isis/citation/CBB220784562/)

Book Rose, Nikolas S.; (2007)
Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century (/isis/citation/CBB000950785/)

Book Tim Carter; (2014)
Merchant Seamen's Health, 1860-1960: Medicine, Technology, Shipowners and the State in Britain (/isis/citation/CBB510390199/)

Book McIvor, Arthur; Johnston, Ronald; (2007)
Miners' Lung. A History of Dust Disease in British Coal Mining (/isis/citation/CBB001022351/)

Article Sarah Wadmann; Amalie Martinus Hauge; (August 2021)
Strategies of stratification: Regulating market access in the era of personalized medicine (/isis/citation/CBB940730003/)

Article Petrus Kautto; Helena Valve; (2019)
Cosmopolitics of a Regulatory Fit: The Case of Nanocellulose (/isis/citation/CBB546323901/)

Article Rita Giuffredi; (2016)
La transizione dall’«Europa della conoscenza» all’«Unione dell’Innovazione» nella politica della ricerca europea (/isis/citation/CBB286815072/)

Article Omar Larentis; (2022)
Green Pass versus Health Faiths. To travel in confidence with public health (/isis/citation/CBB964081476/)

Book Franco Sotte; (2023)
La politica agricola europea: Storia e analisi (/isis/citation/CBB032966698/)

Article Karolin S. Follis; (November 2017)
Vision and Transterritory: The Borders of Europe (/isis/citation/CBB478284294/)

Article Nerea Calvillo; (June 2018)
Political airs: From monitoring to attuned sensing air pollution (/isis/citation/CBB938785365/)

Book Olof Hallonsten; (2020)
The Campaign: How a European Big Science facility ended up on the peripheral farmlands of Southern Sweden (/isis/citation/CBB053703715/)

Article Marjolein Lanzing; Elisa Lievevrouw; Lotje Siffels; (2022)
It Takes Two to Techno-Tango: An Analysis of a Close Embrace Between Google/Apple and the EU in Fighting the Pandemic Through Contact Tracing Apps (/isis/citation/CBB332952770/)

Article Alison Cool; (August 2019)
Impossible, unknowable, accountable: Dramas and dilemmas of data law (/isis/citation/CBB709306750/)

Article Tone Druglitrø; (2022)
Procedural Care: Licensing Practices in Animal Research (/isis/citation/CBB143588294/)

Comments

{{ comment.created_by.username }} on {{ comment.created_on | date:'medium' }}